Results 271 to 279 of about 3,125,328 (279)

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

New England Journal of Medicine, 2011
Thierry Conroy, Marc Ychou, Rosine Guimbaud   +2 more
exaly  

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Ziv Gil
exaly  

Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice

ACS Nano, 2015
Huan Meng, Huiyu Liu, Xiangsheng Liu
exaly  

No gains in efficacy observed by adding gemcitabine to adjuvant therapy for lymph node-positive breast cancer

Ca-A Cancer Journal for Clinicians, 2014
exaly  

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2016
Shaodong Hong, Xuan Wu, Rensheng Wang
exaly  

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Journal of Clinical Oncology, 2007
Rodryg Adam Ramlau, Johan Filip Vansteenkiste   +1 more
exaly  

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Lancet Oncology, The, 2017
Jeremy S Whelan, Penella J Woll, Gareth J Veal   +2 more
exaly  

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

New England Journal of Medicine, 2018
Thierry Conroy, Alice C Wei, Thierry Lecomte   +2 more
exaly  

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

Journal of Clinical Oncology, 2005
exaly